Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings

Atmaca M., Kuloglu M. M., Tezcan E., Unal A.

HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, cilt.17, sa.8, ss.401-405, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 8
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1002/hup.436
  • Dergi Adı: HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.401-405
  • Anahtar Kelimeler: social phobia, citalopram, moclobemide, efficacy, side-effect, LONG-TERM TREATMENT, DOUBLE-BLIND, ANXIETY DISORDER, FLUOXETINE, PAROXETINE, PHARMACOTHERAPY, BROFAROMINE
  • Akdeniz Üniversitesi Adresli: Hayır

Özet

The efficacy of irreversible and reversible monoamine oxidase inhibitors (MAOIs) in the treatment of social phobia (SP) is well established. Recently, selective serotonin reuptake inhibitors (SSRIs) have been used more frequently. In the present study, the efficacy and side-effect profile of citalopram, an SSRI, and moclobemide, the only MAOI used in Turkey, were compared. The 71 patients diagnosed with SP according to DSM-III-R were randomly assigned to two subgroups; citalopram (n = 36) or moclobemide (n = 35). The study was an 8-week, randomized, open-label, rater-blinded, parallel-group trial. All patients were assessed by Hamilton anxiety rating (HAM-A), Liebowitz social anxiety (LSAS), clinical global impression-severity of illness (CGI-SI) and clinical global impression-improvement (CGI-I) scales. There was a similar percentage of responders (citalopram 75%, n = 27 and moclobemide 74.3%, n = 26), with a > 50% or greater reduction in LSAS total score and ratings of 'very much' or 'much improved' on the CGI-I. None of the patients withdrew from the study. The results of the present study suggest that citalopram has shown promising results in patients with SP. Copyright (C) 2002 John Wiley Sons, Ltd.